IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine (CQ) in Brain Metastasis Radiotherapy

Completed · Not applicable

Conditions studied: Brain Metastasis

In brief

This research is being done to determine if a short course of Chloroquine (five weeks) before, during and after whole brain radiation therapy (WBRT) will improve the overall survival of subjects being treated for brain metastases.

Key facts

Study ID

NCT01727531

Run by

Main Line Health

People needed

20

Starts

2008-12-01

Expected to finish

2013-08-01

Last updated by the study team

2015-04-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with histologically confirmed primary solid malignancy
• Patients with single or multiple brain metastases
• Patients with metastasis diameter < 5 cm
• Age > 18
• Clearance from the patient's physician that treatment with chloroquine should not pose a problem to the patient

You may not qualify if…

• Patients with a history of hypotension, cardiomyopathy, epilepsy, seizures
• Patients with impaired renal function
• Patients with psoriasis, porphyria
• Patients with known hypersensitivity to 4-aminoquinoline compounds
• Pregnancy, nursing
• Prior radiotherapy
• During the chloroquine treatment, patients complaining from visual or auditory disturbances, and patients suffering from acute gastrointestinal problems i.e. Anorexia, nausea, vomiting, diarrhea, abdominal cramps

Where it is running

• Lankenau Medical Center — Wynnewood, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.